Peptide conjugates of therapeutically used antitubercular isoniazid - Design, synthesis and antimycobacterial effect

Kata Horváti, G. Mező, Nóra Szabó, F. Hudecz, Sz. Bősze

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow-growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M.tuberculosis from infected phagocytes could be more efficient with target cell-directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T-cell epitope of immundominant 16-kDa protein of M. tuberculosis and tuftsin-derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalJournal of Peptide Science
Volume15
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Isoniazid
Mycobacterium tuberculosis
Peptides
Pathogens
Tuberculosis
Tuftsin
T-Lymphocyte Epitopes
Enzymatic hydrolysis
Chemotherapy
Macrophages
Phagocytes
Pharmaceutical Preparations
Communicable Diseases
Hydrolysis
Blood
Tissue
Drug Therapy
Proteins

ASJC Scopus subject areas

  • Structural Biology
  • Molecular Medicine
  • Molecular Biology
  • Biochemistry
  • Pharmacology
  • Drug Discovery
  • Organic Chemistry
  • Medicine(all)

Cite this

Peptide conjugates of therapeutically used antitubercular isoniazid - Design, synthesis and antimycobacterial effect. / Horváti, Kata; Mező, G.; Szabó, Nóra; Hudecz, F.; Bősze, Sz.

In: Journal of Peptide Science, Vol. 15, No. 5, 2009, p. 385-391.

Research output: Contribution to journalArticle

@article{9370cd4444494e84a083bd1327f5e09c,
title = "Peptide conjugates of therapeutically used antitubercular isoniazid - Design, synthesis and antimycobacterial effect",
abstract = "Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow-growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M.tuberculosis from infected phagocytes could be more efficient with target cell-directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T-cell epitope of immundominant 16-kDa protein of M. tuberculosis and tuftsin-derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety.",
author = "Kata Horv{\'a}ti and G. Mező and N{\'o}ra Szab{\'o} and F. Hudecz and Sz. Bősze",
year = "2009",
doi = "10.1002/psc.1129",
language = "English",
volume = "15",
pages = "385--391",
journal = "Journal of Peptide Science",
issn = "1075-2617",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Peptide conjugates of therapeutically used antitubercular isoniazid - Design, synthesis and antimycobacterial effect

AU - Horváti, Kata

AU - Mező, G.

AU - Szabó, Nóra

AU - Hudecz, F.

AU - Bősze, Sz.

PY - 2009

Y1 - 2009

N2 - Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow-growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M.tuberculosis from infected phagocytes could be more efficient with target cell-directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T-cell epitope of immundominant 16-kDa protein of M. tuberculosis and tuftsin-derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety.

AB - Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis, a slow-growing, powerful human pathogen which can survive in the host macrophages. In the chemotherapy of such intracellular pathogens it is necessary to achieve relatively high level of the drug in blood to attain therapeutically effective concentration in infected cells, which presumably has several serious side effects on healthy tissues. The elimination of M.tuberculosis from infected phagocytes could be more efficient with target cell-directed delivery of antituberculars. A particularly promising approach is to conjugate a drug moiety to a peptide based carrier. The conjugates are chemically constructed to target release by hydrolysis (enzymatic and/or chemical) to liberate the active compound. Here we report the synthesis, characterisation and antimycobacterial evaluation of isoniazid (INH) peptide conjugates. As carrier moiety T-cell epitope of immundominant 16-kDa protein of M. tuberculosis and tuftsin-derived peptides were used. To conjugate INH two synthetic methods were developed, where INH was coupled directly to the peptides or through a heterobifunctional reagent. We found that all of the INH conjugates were effective against M. tuberculosis and the minimal inhibitory concentration (MIC) values were comparable to the free INH moiety.

UR - http://www.scopus.com/inward/record.url?scp=67649240492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649240492&partnerID=8YFLogxK

U2 - 10.1002/psc.1129

DO - 10.1002/psc.1129

M3 - Article

VL - 15

SP - 385

EP - 391

JO - Journal of Peptide Science

JF - Journal of Peptide Science

SN - 1075-2617

IS - 5

ER -